Beneficial Therapeutic Effect of Endothelin-Receptor Antagonist in Generalized Morphea: A Report of Two Cases [0.03%]
内皮素受体拮抗剂治疗泛发性硬化性苔藓疗效观察——2例报告
Leticia Szadai,Nóra Belső,Daniella Hulló et al.
Leticia Szadai et al.
Endothelin receptor antagonists for diabetic kidney disease: back to the future? [0.03%]
糖尿病肾病的内皮素受体拮抗剂治疗：回溯未来？
Panagiota Anyfanti,Marieta Theodorakopoulou,Fotini Iatridi et al.
Panagiota Anyfanti et al.
Introduction: Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease worldwide. Endothelin-1 (ET-1) is a potent vasoconstrictor secreted by vascular endothelial cells, actively involved in the pathophy...
Design and rationale of the efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled trial (EDIT-CAS) [0.03%]
内皮素受体拮抗剂治疗冠状动脉痉挛有效性的设计和原理：一项随机对照试验（编辑CAS）
C Crooijmans,Tpj Jansen,T P van de Hoef et al.
C Crooijmans et al.
Patients with angina and no obstructive coronary artery disease frequently have vasomotor dysfunction as the underlying mechanism for symptoms. Patients with vasomotor dysfunction have a high angina burden and their treatment frequently fai...
Efficacy and safety of endothelin receptor antagonists in non-diabetic kidney nephropathy : A systematic review and meta-analysis [0.03%]
内皮素受体拮抗剂治疗非糖尿病肾小球肾炎的疗效和安全性：系统性回顾和荟萃分析
Jiamei Xu,Congyuan Ma,Xuanwei Li et al.
Jiamei Xu et al.
Background: Recent evidence increasingly confirms the therapeutic potential of endothelin receptor antagonists (ERA) in treating non-diabetic kidney nephropathy. However, clinical data in this area remain limited. Therefo...
Gavin B Chapman,Neeraj Dhaun
Gavin B Chapman
Protective Effects of Bosentan via Endothelin Receptor Antagonism in Experimental Ischemia-Reperfusion Injury in the Lower Limb of Rats [0.03%]
内皮素受体阻断剂博沙坦对大鼠下肢缺血再灌注损伤的保护作用研究
Hüseyin Demirtaş,Abdullah Özer,Mehmet Burak Gülcan et al.
Hüseyin Demirtaş et al.
Objective: This study aimed to evaluate the protective effects of bosentan, a dual endothelin receptor antagonist, against skeletal muscle ischemia-reperfusion injury (IRI) in rats. ...
Xiaoting Ma,Yuyang Liang,Wenmin Chen et al.
Xiaoting Ma et al.
Kidney diseases are among the most prevalent conditions worldwide, impacting over 850 million individuals. They are categorized into acute kidney injury and chronic kidney disease. Current preclinical and clinical trials have demonstrated t...
The Clinical Course of Portopulmonary Hypertension and Outcomes With Endothelin Receptor Antagonist Treatment: Observational Study of Data From the US Organ Procurement and Transplantation Network [0.03%]
布加综合征临床病程及内皮素受体拮抗剂治疗效果的观察性研究：来自美国器官采购和移植网络的数据分析
Hilary M DuBrock,Arun Jose,Sarah Arendse et al.
Hilary M DuBrock et al.
Background: Portopulmonary hypertension (PoPH) occurs in patients with advanced liver disease and can be a contraindication to liver transplant (LT). Improvement of hemodynamic parameters with pulmonary arterial hypertens...
Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs) [0.03%]
血管内皮素受体拮抗剂（ERA）可作为降压药用于缓解小分子酪氨酸激酶抑制剂（TKI）所导致的高血压副作用
Qingjian He,Junling Lin,Chanjuan Mo et al.
Qingjian He et al.
The emergence of targeted anti-tumor drugs has significantly prolonged the lifespan and improved the prognosis of cancer patients. Among these drugs, vascular endothelial growth factor (VEGF) inhibitors, particularly novel small molecule ty...
Ambrisentan [0.03%]
胺舒南酸铵
No information is available on the use of ambrisentan during breastfeeding. Because ambrisentan is more than 99% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinue...
Review
. DOI:
耗时 0.25006 秒，为您在
48229835
条记录里面共找到 1269 篇文章 [XML]